<DOC>
	<DOCNO>NCT00963274</DOCNO>
	<brief_summary>This phase I trial study side effect best dose give bortezomib romidepsin together treat patient chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , indolent B-cell lymphoma , peripheral T-cell lymphoma ( PTCL ) cutaneous T-cell lymphoma ( CTCL ) . Bortezomib romidepsin may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Bortezomib Romidepsin Treating Patients With Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Indolent B-cell Lymphoma , Peripheral T-cell Lymphoma Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) combination bortezomib romidepsin administer weekly x 3 every ( q ) 4wk patient CLL/SLL , indolent B-cell lymphoma , PTCL cutaneous T-cell lymphoma ( CTCL ) . Secondary - Determine safety tolerance describe toxicity combination . - Demonstrate adequate method assessment pharmacodynamic response CLL cell combination respect effect NF-kappa B ( nuclear RelA processing p52 marker p100 process ) , expression NF-kappa B-dependent proteins XIAP Bcl-xL , Bim , document pharmacodynamic response observe course study * Document pharmacodynamic response associate regimen patient . - Document anticancer activity regimen patient . OUTLINE : Patients receive bortezomib IV 3-5 second romidepsin IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood sample patient chronic lymphocytic leukemia collect baseline day 1 course 1 study treatment pharmacodynamic correlative laboratory study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : * Diagnosis 1 follow : CLL SLL , relapse refractory Indolent Bcell lymphoma , relapse refractory : Follicle center lymphoma , follicular diffuse Marginal zone Bcell lymphoma ( splenic , nodal , extranodal [ include mucosa associate lymphoid tissue ( MALT ) ] ) Lymphoplasmacytic lymphoma PTCL , relapse refractory : Anaplastic large cell lymphoma , anaplastic lymphoma kinase ( ALK ) positive Anaplastic large cell lymphoma , ALKnegative Angioimmunoblastic Tcell lymphoma Enteropathyassociated Tcell lymphoma Extranodal natural killer ( NK ) /Tcell lymphoma , nasal type Hepatosplenic Tcell lymphoma PTCL , otherwise specify ( NOS ) Subcutaneous panniculitislike Tcell lymphoma CTCL : * CTCL subtypes mycosis fungoides Stage IB high , Sézary syndrome , primary cutaneous anaplastic large cell lymphoma fail previous systemic treatment , per follow : Stage IA plaque , IB , IIA : At least 4 prior conventional and/or experimental regimen ( topical systemic , include psoralenultraviolet light [ PUVA ] systemic corticosteroid ) Stage IIB , III , IV : At least 1 prior systemic regimen ( systemic corticosteroid alone PUVA alone count systemic regimen purpose ) NOTE : Repeated use regimen consider 1 regimen Prior allogeneic stem cell transplant allow provide follow condition meet : &gt; = 6 month elapse since allogeneic transplant No Graft v . Host Disease ( GVHD ) present Not currently immunosuppressive therapy No prior concurrent CNS malignancy PATIENT CHARACTERISTICS : ECOG performance status 01 ANC &gt; 1,500/mm^3 Platelet count &gt; 75,000/mm^3 Hemoglobin &gt; 7.5 g/dL ( transfusion allow ) Serum creatinine ≤ 1.2 mg/dL actual calculate creatinine clearance &gt; 60 mL/min AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ ULN Serum potassium ≥ 3.5 mEq/L ( supplementation allow ) Serum magnesium ≥ 1.7 mEq/L ( supplementation allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception Willing able comply protocol requirement No prior severe allergic reaction bortezomib , boron , mannitol , romidepsin No progress toxicity secondary bortezomib No grade 1 peripheral neuropathy pain ≥ grade 2 peripheral neuropathy NCICTCAE criterion ( v4.0 ) within past 14 day No condition relate ischemic heart disease , heart failure , risk torsades de pointes sudden cardiac death , include follow : History sustain ventricular tachycardia , ventricular fibrillation , torsades de pointes , resuscitate cardiac arrest unless currently address implantable cardiac defibrillator Baseline heart rate &gt; 140 beat per minute Known congenital long QT syndrome QTc interval &gt; 480 millisecond Type II seconddegree atrioventricular ( AV ) block , thirddegree AV block , ventricular rate &lt; 50 beat per minute Myocardial infarction within past 6 month Patients myocardial infarction 612 month ago eligible provide asymptomatic negative cardiac risk assessment ( i.e. , treadmill stress test , nuclear medicine stress test , stress echocardiogram ) Angina upon ordinary physical activity Angina strenuous , rapid , prolonged exertion allow ECG evidence cardiac ischemia , define follow : ST depression ≥ 2 mm , measure isoelectric line ST segment Twave inversion ≥ 4 mm , measure isoelectric line peak Twave NYHA class IIIV congestive heart failure Known leave ventricular ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram MRI Known hypertrophic cardiomegaly restrictive cardiomyopathy No uncontrolled hypertension , define persistent blood pressure ≥ 160/95 mm Hg despite medical management No clinically significant active infection , include know HIV infection hepatitis B C No malignancy within past 3 year except completely resect basal cell carcinoma squamous cell carcinoma skin , situ malignancy , curatively treat lowrisk prostate cancer No concurrent medical condition , investigator 's opinion , would compromise study treatment assessment toxicity PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior chemotherapy , radiation therapy investigational agent . If steroids cancer control use , patient must theses agent least 1 week start treatment . ( Maintenance therapy nonmalignant disease prednisone steroid equivalent dose le 10 mg/day permit ) Prior allogeneic stem cell transplantation allow provide follow condition meet : Greater equal 6 month elapse since allogeneic transplant No Graft v . Host Disease ( GVHD ) present More 4 week since prior bortezomib No concurrent oral hormonal contraceptive No concurrent potent moderate CYP3A4 inhibitor No concurrent antiarrhythmic agent No concurrent treatment drug generally accept risk cause torsades de pointes ( class 1 drug ) Class 2 3 drug allow discretion investigator No concurrent systemic therapy malignancy Concurrent warfarin ( coumadin ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>hepatosplenic T-cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
</DOC>